Park Square is pleased to announce the placement of Charles Allerson, Ph.D., as Chief Technology Officer at Switch Therapeutics.
| less than a minute read
Switch Therapeutics appoints Charles Allerson, Ph.D., as Chief Technology Officer
Get in touch
Get in touch
Switch Therapeutics, a biotechnology company pioneering a new way to use RNA science to treat diseases utilizing its proprietary CASi (Conditionally Activated siRNA) platform, today announced the appointment of Charles Allerson, Ph.D., as Chief Technology Officer (CTO).
Get in touch
Get in touch
Latest Insights
/Passle/58a5cb8db00e8110e83aa395/SearchServiceImages/2026-08-19-20-29-57-758-6a8612450e2b381c3863fcf2.jpg)
/Passle/58a5cb8db00e8110e83aa395/MediaLibrary/Images/2026-08-04-15-32-04-091-6a7205f4b4306b41266d92f2.jpg)
/Passle/58a5cb8db00e8110e83aa395/MediaLibrary/Images/2026-08-04-18-23-13-222-6a722e11663e81e26a6b2c3e.jpg)
